Etanercept was developed by researchers at biotechnology company Immunex, which was subsequently purchased by Amgen. It was released in 1999, soon after the release of infliximab (Remicade) – the first chimeric monoclonal antibody against TNFα to be marketed for clinical use.
Mode of action
Tumor necrosis factor-alpha (TNFα) is a cytokine produced by monocytes and macrophages, two types of white blood cells. It mediates the immune response by increasing the transport of white blood cells to sites of inflammation. Inhibition of its action by etanercept reduces the inflammatory response which is especially useful for treating autoimmune diseases.
More on [ Etanercept ]
WL Issued to Amrex Zetron Inc FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Amrex Zetron Inc on 14 Apr 2009 by Los Angeles District Office WL Issued to Coast Institutional Review Board FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Branitz, Bruce, MD FDA Thu, 09 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Cote, Charles J., MD FDA Mon, 02 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Cote, Charles J., MD on 02 Mar 2009 by Center for Drug Evaluation and Research WL Issued to Genzyme Corporation FDA Fri, 27 Feb 2009 00:00:00 -0400 FDA Warning Letter Issued to Genzyme Corporation on 27 Feb 2009 by New England District Office WL Issued to Hammill Manufacturing Company FDA Tue, 06 Jan 2009 00:00:00 -0400 FDA Warning Letter Issued to Hammill Manufacturing Company on 06 Jan 2009 by Cincinnati District Office
CFDA: FDA Latest Drug GCP Warning Letters
WL Issued to Coast Institutional Review Board FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Branitz, Bruce, MD FDA Thu, 09 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Bukowski, Ronald M, MD FDA Mon, 30 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Bukowski, Ronald M, MD on 30 Mar 2009 by Center for Drug Evaluation and Research WL Issued to Youabian, Inc FDA Tue, 17 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Youabian, Inc on 17 Mar 2009 by Los Angeles District Office WL Issued to Provena St. Joseph's Medical Center IRB FDA Thu, 12 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Provena St. Joseph's Medical Center IRB on 12 Mar 2009 by Center for Biologics Evaluation and Research WL Issued to Paulson, Daniel M., MD FDA Wed, 11 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Paulson, Daniel M., MD on 11 Mar 2009 by Center for Drug Evaluation and Research